{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for pantothenic root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT03758612: Phase 1 Interventional Completed Tuberculosis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03163966: Phase 2 Interventional Completed Rheumatoid Arthritis, DMARD-naive and Early Disease Patients
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04279574: Not Applicable Interventional Completed Dental Cements
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:fipravirimat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02423577: Phase 2 Interventional Completed Influenza
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:linvencorvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03500263: Phase 1/Phase 2 Interventional Completed Cystic Fibrosis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:bimatoprost grenod [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:admilparant [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02561091: Phase 3 Interventional Completed Hearing Loss
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
XG-102 (also known as brimapitide), a D-stereoisomer of a c-Jun-N-terminal kinase-1111 was developed in a biocompatible gel formulation for the treatment of sudden sensorineural hearing loss with a single-dose administration into the middle ear. It’s a cell-penetrating peptide which inhibits the JNK stress kinase. JNK is activated following various types of cochlear insults (stress) that cause acute inner ear hearing loss and plays a key role in apoptosis of sensory cells as well as in inflammatory responses. By blocking JNK, AM-111 protects stress-injured cochlear cells and helps to prevent or reduce chronic hearing loss. Auris Medical's otoprotective drug AM-111 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of acute sensorineural hearing loss (ASNHL), a condition which may occur following various inner ear injuries. In addition, XG-102 was studied in phase III clinical trials in the treatment of acute inner ear hearing loss and in the reduction of post-cataract surgery intraocular inflammation. Besides, XG-102 is advancing through pre-clinical development with programs in ocular inflammation, urology, nephrology and Alzheimer’s disease.
